New research shows that long-term Tysabri treatment of relapsing multiple sclerosis improves physical and mental health and leads to greater satisfaction with therapy.
Patients with MS experience ... Read more
Merck KGaA, Darmstadt, Germany recently announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the company’s investigational product Cladribine Tablets as ... Read more
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recommended marketing authorization to Zinbryta (daclizumab) for the treatment of ... Read more
Genzyme recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing that Aubagio® (teriflunomide) was able to slow the ... Read more
Merck recently reported its intention to file for European registration of its product candidate for relapsing multiple sclerosis – Cladribine, a synthetic anti-cancer agent able to suppress the ... Read more
Novartis will present novel Gilenya data, demonstrating the company’s methods for assessing the impact of relapsing multiple sclerosis (RMS) in both patients and physicians, during the 67th Annual Meeting of American ... Read more
Pin It on Pinterest